B2M and melanoma: Genetic alterations in antigen presentation (B2M, HLA-A) and IFNγ signaling (IFNGR, STAT1 and JAK1/2) in non-responding melanoma patients9,11–13 are uncommon, and not restricted to non-responding patients13,37,38.